Prognostic values of aldehyde dehydrogenase 1 isoenzymes in ovarian cancer

Yu-mei Ma¹
Shan Zhao²
¹Department of Pathology
²Department of Cancer Second Division, The Second Hospital of Hebei Medical University, Shijiazhuang City, People’s Republic of China

Abstract: Aldehyde dehydrogenase 1 (ALDH1) activity has been used as a functional stem cell marker to isolate cancer stem cells in different cancer types, including ovarian cancer. However, which ALDH1’s isoenzymes are contributing to ALDH1 activity in ovarian cancer remains elusive. In addition, the prognostic value of an individual ALDH1 isoenzyme in ovarian cancer is not clear. Thus, we accessed the prognostic value of ALDH1 isoenzymes in ovarian cancer patients through the “Kaplan–Meier plotter” online database, which can be used to determine the effect of the genes on ovarian cancer prognosis. We found that high mRNA expression of five ALDH1 isoenzymes, such as ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, and ALDH1L1, was not correlated with overall survival (OS) for all 1,306 ovarian cancer patients. In addition, all five of the ALDH1 isoenzymes’ high mRNA expression was found to be uncorrelated with OS in serous cancer or endometrioid cancer patients. However, ALDH1A3’s high mRNA expression is significantly associated with worse OS in grade II ovarian cancer patients, hazard ratio (HR) 1.53 (1.14–2.07), \( P=0.005 \). ALDH1A2’s high mRNA expression is significantly associated with worse OS in TP53 wild-type ovarian cancer patients, HR 2.86 (1.56–5.08), \( P=0.00036 \). In addition, ALDH1A3’s high mRNA expression is significantly associated with better OS in TP53 wild-type ovarian cancer patients, HR 0.56 (0.32–1.00), \( P=0.04 \). Our results indicate that although ALDH1 isoenzyme mRNA might not be a prognostic marker for overall ovarian cancer patients, some isoenzymes, such as ALDH1A2 and ALDH1A3, might be a good prognostic marker for some types of ovarian cancer patients.

Keywords: ALDH1, cancer stem cell, prognosis, KM plotter, hazard ratio

Introduction

Ovarian cancer ranks fourth among the causes of cancer deaths in women and is the seventh most common cancer in women. It was predicted that >14,030 women will die of ovarian cancer and ~22,240 new cases of ovarian cancer were diagnosed in the USA in 2013.¹ Most ovarian malignancies have epithelial origins² and are further grouped into histological types as follows: serous, mucinous, clear cell, endometrioid, carcinosarcoma, transitional cell tumors (Brenner tumors), mixed epithelial tumor, undifferentiated carcinoma, and others. Despite advances in early diagnosis, cytotoxic chemotherapy, radical cure operation, and targeted therapeutic treatment, there are still ~85% of ovarian cancer patients who would develop recurrent disease, after achieving a full remission following the first-line therapy.³⁴ Thus, the identification on the mechanism of initiation, progression, as well as investigation of differential diagnostic prognostic marker and potential drug target, is still needed and will help to provide better prognosis and individualized treatments.

Elevated aldehyde dehydrogenase 1 (ALDH1) activity has been detected in the stem cell populations of human acute myeloid leukemia, multiple myeloma, and a number...
of solid tumors. A number of reports have also shown that increased ALDH1 expression was detected in some ovarian cancer cell lines and ovarian tumor tissues. Therefore, examination of ALDH1 activity shows promising results as a universal marker for both normal and malignant stem cell populations, including ovarian cancer. The ALDH1 family is composed of enzymes that contribute to the oxidation of retinol to retinoic acid in stem cell differentiation; which individual ALDH1’s isozyme is a major isozyme in ovarian cancer and contribute to ALDH1 activity has not been determined. Furthermore, the prognostic role of individual ALDH1 isoename in ovarian cancer remains elusive.

OncoTargets and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 01-Mar-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Materials and methods

We used the KM plotter online database to determine the relevance of individual ALDH1 members’ messenger RNA (mRNA) expression to overall survival (OS) of ovarian cancer patients. The Hebei Medical University Institutional Review Board deemed this retrospective study exempt from ethical approval and patient consent due to patient data being de-identified. Currently, the database includes breast cancer, lung cancer, gastric cancer, as well as ovarian cancer data. Ovarian cancer patients in the database were identified from the cancer Biomedical Informatics Grid (http://cabicancer.gov/), microarray samples are published in the caArray project, on The Cancer Genome Atlas (http://cancergenome.nih.gov), and the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) ovarian cancer datasets. They provided clinical data, including age, histology, grade, stage, TP53 mutation status, and applied chemotherapy for all patients in WinStat 2013. The ovarian cancer patients were followed up for 20 years. The database was integrated using gene expression data and survival information of 1,306 ovarian cancer patients. Briefly, five ALDH1 sub-members (ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, and ALDH1L1) were entered into the database (http://kmplot.com/analysis/index.php?p=service&cancer=ovar) to obtain Kaplan–Meier survival plots. Certain gene mRNA expression above or below the median separates the cases into high expression and low expression. Hazard ratio (HR), 95% confidence intervals, and logrank P were calculated and displayed on the webpage.

Results

The ALDH1 family is composed of six submembers. As previously indicated, only ALDH1L2 among all the six ALDH1 isoenzymes was not found in www.kmplot.com, probably due to its low expression in cancer tissues. We first accessed the prognostic value of ALDH1A1’s mRNA expression. The desired Affymetrix ID is valid: 212224_at (ALDH1A1). Survival curves are plotted for all patients (n=1,306; Figure 1A), for serous cancer patients (n=1,019; Figure 1B), and for endometrioid cancer patients (n=36; Figure 1C). ALDH1A1’s high mRNA expression was found to be uncorrelated with OS for all ovarian cancer patients followed for 20 years, HR 1.00 (0.77–0.99), P=0.98. In addition, ALDH1A1’s high mRNA expression was also found to be uncorrelated with OS in serous cancer patients, HR 0.96 (0.82–1.11), P=0.57, and in endometrioid cancer patients, HR 0.46 (0.17–1.28), P=0.13.

We then accessed the prognostic value of ALDH1A2’s mRNA expression. The desired Affymetrix ID is valid: 207015_s_at (ALDH1A2). ALDH1A2’s high mRNA expression was found to be uncorrelated with OS for all ovarian cancer patients, HR 1.02 (0.89–1.16), P=0.79 (Figure 2A). In addition, ALDH1A2’s high mRNA expression was also found to be uncorrelated with OS in serous cancer patients, HR 1.14 (0.98–1.33), P=0.087 (Figure 2B), and in endometrioid cancer patients, HR 1.17 (0.44–3.13), P=0.75 (Figure 2C).

Figure 3 shows the prognostic value of ALDH1A3’s mRNA expression. The desired Affymetrix ID is valid: 203180_at (ALDH1A3). The curves show that ALDH1A3 expression above or below the median does not separate the cases into significantly different prognostic groups in ovarian cancer patients, HR 1.08 (0.95–1.24), P=0.22 (Figure 3A); serous cancer patients, HR 1.13 (0.97–1.31), P=0.12 (Figure 3B); or endometrioid cancer patients, HR 0.41 (0.14–1.18), P=0.086 (Figure 3C).

Figure 4 shows the prognostic value of ALDH1B1’s mRNA expression. The desired Affymetrix ID is valid: 209646_x_at (ALDH1B1). ALDH1B1’s high mRNA expression was found to be uncorrelated with OS for all ovarian cancer patients, HR 1.02 (0.9–1.17), P=0.74 (Figure 4A). In addition, ALDH1B1’s
high mRNA expression was also found to be uncorrelated with OS in serous cancer patients, HR 1.11 (0.95–1.29), \(P=0.19\) (Figure 4B), and in endometrioid cancer patients, HR 1.2 (0.45–3.2), \(P=0.72\) (Figure 4C).

Finally, we accessed the prognostic value of ALDH1L1’s mRNA expression. The desired Affymetrix ID is valid: 205208_at (ALDH1L1). The curves show that ALDH1L1 expression above or below the median does not separate
Figure 3 The prognostic value of ALDH1A3 expression.

Notes: The desired Affymetrix ID is valid: 203180_at (ALDH1A3). Survival curves are plotted for (A) all patients (n=1,306), (B) serous cancer patients (n=1,019), and (C) endometrioid cancer patients (n=36).

Abbreviations: ALDH1, aldehyde dehydrogenase 1; HR, hazard ratio.

The cases into significantly different prognostic groups in ovarian cancer patients, HR 0.91 (0.8–1.04), P=0.17 (Figure 5A); serous cancer patients, HR 1.04 (0.89–1.2), P=0.66 (Figure 5B); or endometrioid cancer patients, HR 0.59 (0.21–1.62), P=0.3 (Figure 5C).

To further access the correlation of individual ALDH1 isoenzymes with other clinicopathological features, we valuated the correlation with pathological grades (Table 1), clinical grades (Table 2), and TP53 mutation (Table 3) of ovarian cancer patients. As observed in Table 1, all the
individual ALDH1 except ALDH1A3 is not significantly associated with pathological grades of ovarian cancer patients. ALDH1A3’ high mRNA expression is associated with worse OS in grade II ovarian cancer patients, HR 1.53 (1.14–2.07), \( P = 0.005 \). As observed in Table 2, all the individual ALDH1 is not significantly associated with clinical stages of ovarian cancer patients. We find from Table 3 that ALDH1A2’s high mRNA expression is significantly associated with worse OS in TP53 wild-type ovarian cancer patients, HR 2.86 (1.56–5.08), \( P = 0.00036 \). In addition, ALDH1A3’s high mRNA expression is significantly associated with better OS in TP53 wild-type ovarian cancer patients, HR 0.56 (0.32–1.00), \( P = 0.04 \).

**Table 1** Correlation of ALDH1 isoenzymes with pathological grades of ovarian cancer patients as a result of Kaplan-Meier analysis

<table>
<thead>
<tr>
<th>Isoenzymes</th>
<th>Pathological grades</th>
<th>Cases</th>
<th>HR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALDH1A1</td>
<td>I</td>
<td>37</td>
<td>0.8 (0.27–2.38)</td>
<td>0.68</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>247</td>
<td>1.11 (0.82–1.49)</td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>790</td>
<td>0.87 (0.73–1.04)</td>
<td>0.12</td>
</tr>
<tr>
<td>ALDH1A2</td>
<td>I</td>
<td>37</td>
<td>1.55 (0.5–4.76)</td>
<td>0.44</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>247</td>
<td>1.21 (0.9–1.63)</td>
<td>0.21</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>790</td>
<td>1.14 (0.96–1.35)</td>
<td>0.14</td>
</tr>
<tr>
<td>ALDH1A3</td>
<td>I</td>
<td>37</td>
<td>1.17 (0.39–3.5)</td>
<td>0.77</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>247</td>
<td>1.53 (1.14–2.07)</td>
<td>0.005</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>790</td>
<td>1.08 (0.91–1.29)</td>
<td>0.37</td>
</tr>
<tr>
<td>ALDH1B1</td>
<td>I</td>
<td>37</td>
<td>1.69 (0.55–5.17)</td>
<td>0.36</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>247</td>
<td>1.19 (0.88–1.6)</td>
<td>0.26</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>790</td>
<td>1.09 (0.92–1.29)</td>
<td>0.33</td>
</tr>
<tr>
<td>ALDH1L1</td>
<td>I</td>
<td>37</td>
<td>3.28 (0.9–11.95)</td>
<td>0.056</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>247</td>
<td>1.12 (0.83–1.51)</td>
<td>0.45</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>790</td>
<td>1 (0.8–1.19)</td>
<td>0.99</td>
</tr>
</tbody>
</table>

**Table 2** Correlation of ALDH1 isoenzymes with clinical stages of ovarian cancer patients as a result of Kaplan-Meier analysis

<table>
<thead>
<tr>
<th>Isoenzymes</th>
<th>Clinical stages</th>
<th>Cases</th>
<th>HR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALDH1A1</td>
<td>I-II</td>
<td>126</td>
<td>0.59 (0.32–1.09)</td>
<td>0.087</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>846</td>
<td>0.99 (0.84–1.16)</td>
<td>0.88</td>
</tr>
<tr>
<td></td>
<td>IV</td>
<td>143</td>
<td>1 (0.67–1.5)</td>
<td>1</td>
</tr>
<tr>
<td>ALDH1A2</td>
<td>I-II</td>
<td>126</td>
<td>1.66 (0.9–3.07)</td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>846</td>
<td>1.05 (0.9–1.24)</td>
<td>0.54</td>
</tr>
<tr>
<td></td>
<td>IV</td>
<td>143</td>
<td>1.18 (0.79–1.76)</td>
<td>0.43</td>
</tr>
<tr>
<td>ALDH1A3</td>
<td>I-II</td>
<td>126</td>
<td>0.83 (0.46–1.51)</td>
<td>0.55</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>846</td>
<td>1.16 (0.99–1.36)</td>
<td>0.074</td>
</tr>
<tr>
<td></td>
<td>IV</td>
<td>143</td>
<td>0.96 (0.64–1.44)</td>
<td>0.85</td>
</tr>
<tr>
<td>ALDH1B1</td>
<td>I-II</td>
<td>126</td>
<td>1.8 (0.98–3.31)</td>
<td>0.054</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>846</td>
<td>1.02 (0.87–1.2)</td>
<td>0.82</td>
</tr>
<tr>
<td></td>
<td>IV</td>
<td>143</td>
<td>0.87 (0.58–1.31)</td>
<td>0.51</td>
</tr>
<tr>
<td>ALDH1L1</td>
<td>I-II</td>
<td>126</td>
<td>0.73 (0.43–1.22)</td>
<td>0.29</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>846</td>
<td>1.08 (0.92–1.27)</td>
<td>0.35</td>
</tr>
<tr>
<td></td>
<td>IV</td>
<td>143</td>
<td>1.01 (0.68–1.52)</td>
<td>0.94</td>
</tr>
</tbody>
</table>

**Abbreviations**: ALDH1, aldehyde dehydrogenase 1; HR, hazard ratio; CI, confidence interval.
Discusion

A number of previous studies focused on the relationship between ALDH1A1 protein expression and the clinicopathologic parameters, including prognosis of tumor patients. In most types of tumors, such as lung cancer, colorectal carcinoma, clear cell renal cell carcinoma, esophageal squamous cell carcinoma, breast cancer, gastric cancer, head and neck cancer, and bladder cancer, high expression of ALDH1A1 protein was associated with tumor progression, metastasis, and poor prognosis. In contrast to the earlier studies, there were also a few reports showing that ALDH1A1 is a better prognostic marker in patients suffering from primary glioblastoma. In an early report, Chang et al. observed that in contrast to its function in breast cancer, ALDH1A1 is a favorable prognostic factor in ovarian carcinoma. They believe that ALDH1A1, therefore, may have a different function in ovarian cancer than it does in breast cancer. However, Liebscher et al. revealed that ALDH1A1, together with epidermal growth factor receptor coexpression, is a characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma. However, in a recent study, Huang et al. still consider that high expression of ALDH1A1 in ovarian carcinoma cells may thus portend a favorable prognosis, but its expression in tumor microenvironment may have no role in tumor behavior of ovarian carcinomas. They suggest that more studies are warranted to find out the mechanisms for this.

The prognostic role of ALDH1 isoenzyme mRNA in ovarian cancer patients was not reported. We found that five ALDH1 isoenzymes’, such as ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, and ALDH1L1, high mRNA expression was not to be correlated with OS for all ovarian cancer patients. In addition, all five of the ALDH1 isoenzymes’ high mRNA expression was not found to be correlated with OS in serous cancer and endometrioid cancer patients. However, ALDH1A3’s high mRNA expression is associated with worse OS in grade II ovarian cancer patients, HR 1.53 (1.14–2.07), P=0.005. ALDH1A2’s high mRNA expression is significantly associated with worse OS in TP53 wild-type ovarian cancer patients, HR 2.86 (1.56–5.08), P=0.00036. In addition, ALDH1A3’s high mRNA expression is significantly associated with better OS in TP53 wild-type ovarian cancer patients, HR 0.56 (0.32–1.00), P=0.04. ALDH1L2 is expressed in the brain, heart, liver, kidney, and pancreas tissues by using real-time polymerase chain reaction performed on an array of human tissues, and no information is available for its expression in ovarian tissues. No survival information for ALDH1L2 in ovarian cancer patients is available, probably due to its low expression in normal ovarian tissue and ovarian cancer.

There are strong evidences showing the correlation between p53 function and ovarian cancer stem cells. Kurrey et al. reported that snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Motohara et al. also observed that transient depletion of p53 followed by transduction of c-Myc and KRas converts ovarian stem-like cells into cancer stem cells. Interestingly, ovarian cancer cells display long-term stem cell properties ex vivo and in vivo and express stem and/or progenitor cell markers, ALDH1, LGR5, LEF1, CD133, and CK6B, after inactivation of tumor suppressor genes TP53 and RB1. In our results, we find that ALDH1A2’s high mRNA expression is significantly associated with worse OS in TP53 wild-type ovarian cancer patients. In contrast, ALDH1A3’s high mRNA expression is significantly associated with better OS in TP53 wild-type ovarian cancer patients. The significance of correlation between p53 and individual ALDH1 isoenzymes in ovarian cancer needs further study.

ALDH1 belongs to a family of detoxifying enzymes that convert aldehydes to their corresponding carboxylic acids, and members of this family are present in many types of normal tissues. Currently, the “gold standard” of the measurement of ALDH1’s activity in viable cells is measured by the use of flow cytometry and fluorescent substrates for ALDH1. It is not clear about the role of each ALDH1 isoenzyme that contributes to ALDH1 activity in ovarian cancer cells. It will be helpful to know which ALDH1 isoenzyme contributes to ALDH1 activity if we measure the changes in ALDH1 activity upon using small interfering RNAs or antibodies of individual ALDH1 isoenzymes in...
ovarian cancer cells. Our current study found that unlike breast cancer, ALDH1A1 mRNA in ovarian cancer is not associated with poor prognosis. Our current study supports that ALDH1A2 and ALDH1A3 might be major contributors to the ALDH1 activity in ovarian cancer, since ALDH1A2 and ALDH1A3’s high mRNA expression was found to be significantly correlated with worse OS for some type of ovarian cancer patients. The analysis of ALDH1A1 expression will also be important for the design of treatment and the assessment of the prognosis of ovarian cancer patients by using high-quality commercial antibodies against ALDH1A1.

Please note that ALDH1 mRNA was extracted from cancer tissues, which were composed of many type of cells, such as different types of stromal cells and epithelial cells. Thus, ALDH1 isoenzymes’ mRNA expression in the individual cell types may be different. In a recent report, Isfoss et al analyzed immunohistologically for the stem cell marker, ALDH1A1, in different forms of bladder neoplasia and observed that the majority of stem cell marker-positive cells were located in the connective tissue and a smaller fraction in the epithelial tissue. Stem cell marker-positive cells with nonstem cell character included stellate cells, mast cells, endothelial cells, foamy histiocytes, and neurons. Therefore, it is interesting to further study the role and clinical significance of the individual ALDH1 isoenzymes in different types of cells.

Disclosure
The authors have no financial involvement with any organization or entity with a financial interest in the subject matter or materials discussed in the manuscript. The authors reported no conflicts of interest in this work.

References


